548
Participants
Start Date
October 17, 2016
Primary Completion Date
February 18, 2020
Study Completion Date
February 21, 2020
Altoida: neuropsychological, MRI, EEG and CSF biomarkers
"Data collection at baseline: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects. In both Prodromal and Preclinical AD subjects, APOE genotyping. The local clinical Unit should document the positivity at the baseline session of at least one of the biomarkers of AD mentioned above.~Data collection at 6, 12, 24 and 36 months of follow up: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects."
Lead Sponsor
Collaborators (1)
Greek Alzheimer's Association and Related Disorders
OTHER
University of Roma La Sapienza
OTHER
IRCCS Centro San Giovanni di Dio Fatebenefratelli
OTHER
Neuromed IRCCS
OTHER
Scripps Health
OTHER
Global Brain Health Institute (GBHI)
OTHER
Takeda Pharmaceuticals International, Inc.
INDUSTRY
Research Center on Computational BioMarkers
OTHER
Bioinformatics and Human Electrophysiology Laboratory
OTHER
Fundacion Clinic per a la Recerca Biomédica
OTHER
University of Dublin, Trinity College
OTHER
University of Barcelona
OTHER
EIT Health
OTHER
Klinik Hirslanden, Zurich
OTHER
The University of Texas at Dallas
OTHER
Altoida
INDUSTRY